genetically modified organisms

Pharmalot By Ed Silverman

Insufficient progress is being made in reporting clinical trial results in the U.S.

Politics By Rachel Cohrs

Key senators propose an overhaul of how the U.S. prepares for pandemics

Health Tech By Casey Ross and Katie Palmer

Telehealth lobbying is soaring to new heights

Pharmalot By Ed Silverman

What risks? FDA scolds Lilly for misleading Instagram post about a best-selling diabetes drug

Pharma By Ed Silverman

Pharmalittle: Pfizer and BioNTech start trial of Omicron-targeted vaccine; insulin makers boost lobbying spending

Biotech By Adam Feuerstein

Pivotal study shows Sierra Oncology drug improves anemia and other symptoms of myelofibrosis

Health By Matthew Herper

As Pfizer and BioNTech begin clinical trial of Omicron-based vaccine, timeline to authorization is unclear

First Opinion By Amir Mokhtari

Learning from Covid-19 requires a modeling renaissance